Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors

被引：11
|
作者：
Sobecki-Rausch, Janelle [1 ]
Barroilhet, Lisa [1 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Div Gynecol Oncol, 600 Highland Ave, Madison, WI 53792 USA
来源：
CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2019年 / 20卷 / 11期
关键词：
Anti-PD-1; treatment; Endometrial cancer; Microsatellite instability; Mismatch repair deficiency; Pembrolizumab; IMMUNE CHECKPOINT INHIBITORS; LYNCH SYNDROME; OPEN-LABEL; PEMBROLIZUMAB; SAFETY;
D O I：
10.1007/s11864-019-0679-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Among gynecologic malignancies, mismatch repair-deficient endometrial cancers show the greatest response to anti-programmed cell death-1 (PD-1) antibodies, such as pembrolizumab. Routine immunohistochemical (IHC) and molecular testing should be performed on all endometrial cancers at the time of diagnosis in order to identify endometrial cancers with mismatch repair deficiency that may show improved response to anti-PD-1 therapy in the progressive or metastatic setting. Institutional effort to enroll patients in clinical trials investigating the use of immune checkpoint inhibitors in endometrial cancer should be prioritized.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability–High Tumors
    Janelle Sobecki-Rausch
    Lisa Barroilhet
    Current Treatment Options in Oncology, 2019, 20
  • [2] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [3] Autoimmune diabetes and anti-programmed cell death-1 (anti-PD-1) cancer immunotherapy
    Daltry, S.
    Bujanova, J.
    Cranston, I.
    DIABETIC MEDICINE, 2017, 34 : 102 - 102
  • [4] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    Yang, Lu-Lu
    Wu, Yi-Long
    LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
  • [5] Anti-programmed cell death-1 therapy in nonmelanoma skin cancer
    Winkler, J. K.
    Schneiderbauer, R.
    Bender, C.
    Sedlaczek, O.
    Froehling, S.
    Penzel, R.
    Enk, A.
    Hassel, J. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (02) : 498 - 502
  • [6] Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Wang, Yun
    Zou, Xue-Bin
    Chen, Shi
    Li, Shu-Man
    Duan, Jin-Ling
    Zhou, Jie
    Chen, Guo-Ming
    Luo, Tian-Qi
    Zhou, Zhi-Wei
    Li, Yuan-Fang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [7] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Naidoo, Jarushka
    Wang, Xuan
    Woo, Kaitlin M.
    Iyriboz, Tunc
    Halpenny, Darragh
    Cunningham, Jane
    Chaft, Jamie E.
    Segal, Neil H.
    Callahan, Margaret K.
    Lesokhin, Alexander M.
    Rosenberg, Jonathan
    Voss, Martin H.
    Rudin, Charles M.
    Rizvi, Hira
    Hou, Xue
    Rodriguez, Katherine
    Albano, Melanie
    Gordon, Ruth-Ann
    Leduc, Charles
    Rekhtman, Natasha
    Harris, Bianca
    Menzies, Alexander M.
    Guminski, Alexander D.
    Carlino, Matteo S.
    Kong, Benjamin Y.
    Wolchok, Jedd D.
    Postow, Michael A.
    Long, Georgina V.
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +
  • [8] Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer
    Marginean, Esmeralda Celia
    Melosky, Barbara
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (01) : 26 - 34
  • [9] Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy
    Ariyasu, Ryo
    Horiike, Atsushi
    Yoshizawa, Takahiro
    Dotsu, Yosuke
    Koyama, Junji
    Saiki, Masafumi
    Sonoda, Tomoaki
    Nishikawa, Shingo
    Kitazono, Satoru
    Yanagitani, Noriko
    Nishio, Makoto
    ANTICANCER RESEARCH, 2017, 37 (08) : 4229 - 4232
  • [10] Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Li, Yuanfang
    Chen, Yingbo
    Zhou, Zhiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345